questionsmedicales.fr
Acides nucléiques, nucléotides et nucléosides
Nucléotides
Ribonucléotides
Nucléotides uridyliques
Uridine diphosphate
Uridine diphosphate : Questions médicales fréquentes
Termes MeSH sélectionnés :
REM Sleep Behavior Disorder
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate : Questions médicales les plus fréquentes",
"headline": "Uridine diphosphate : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Uridine diphosphate : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-22",
"dateModified": "2025-04-18",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Nucléotides uridyliques",
"url": "https://questionsmedicales.fr/mesh/D014500",
"about": {
"@type": "MedicalCondition",
"name": "Nucléotides uridyliques",
"code": {
"@type": "MedicalCode",
"code": "D014500",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate ose",
"alternateName": "Uridine Diphosphate Sugars",
"url": "https://questionsmedicales.fr/mesh/D014539",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate ose",
"code": {
"@type": "MedicalCode",
"code": "D014539",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate N-acétylgalactosamine",
"alternateName": "Uridine Diphosphate N-Acetylgalactosamine",
"url": "https://questionsmedicales.fr/mesh/D014536",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate N-acétylgalactosamine",
"code": {
"@type": "MedicalCode",
"code": "D014536",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate N-acétylglucosamine",
"alternateName": "Uridine Diphosphate N-Acetylglucosamine",
"url": "https://questionsmedicales.fr/mesh/D014537",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate N-acétylglucosamine",
"code": {
"@type": "MedicalCode",
"code": "D014537",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.120"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Acide uridine diphosphate N-acétylmuramique",
"alternateName": "Uridine Diphosphate N-Acetylmuramic Acid",
"url": "https://questionsmedicales.fr/mesh/D014538",
"about": {
"@type": "MedicalCondition",
"name": "Acide uridine diphosphate N-acétylmuramique",
"code": {
"@type": "MedicalCode",
"code": "D014538",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.150"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate galactose",
"alternateName": "Uridine Diphosphate Galactose",
"url": "https://questionsmedicales.fr/mesh/D014531",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate galactose",
"code": {
"@type": "MedicalCode",
"code": "D014531",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate glucose",
"alternateName": "Uridine Diphosphate Glucose",
"url": "https://questionsmedicales.fr/mesh/D014532",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate glucose",
"code": {
"@type": "MedicalCode",
"code": "D014532",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.350"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Acide uridine diphosphate glucuronique",
"alternateName": "Uridine Diphosphate Glucuronic Acid",
"url": "https://questionsmedicales.fr/mesh/D014535",
"about": {
"@type": "MedicalCondition",
"name": "Acide uridine diphosphate glucuronique",
"code": {
"@type": "MedicalCode",
"code": "D014535",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.375"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate xylose",
"alternateName": "Uridine Diphosphate Xylose",
"url": "https://questionsmedicales.fr/mesh/D014540",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate xylose",
"code": {
"@type": "MedicalCode",
"code": "D014540",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.800"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate",
"alternateName": "Uridine Diphosphate",
"code": {
"@type": "MedicalCode",
"code": "D014530",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Takayuki Matsumoto",
"url": "https://questionsmedicales.fr/author/Takayuki%20Matsumoto",
"affiliation": {
"@type": "Organization",
"name": "Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan. Electronic address: t-matsu@hoshi.ac.jp."
}
},
{
"@type": "Person",
"name": "Kumiko Taguchi",
"url": "https://questionsmedicales.fr/author/Kumiko%20Taguchi",
"affiliation": {
"@type": "Organization",
"name": "Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan."
}
},
{
"@type": "Person",
"name": "Tsuneo Kobayashi",
"url": "https://questionsmedicales.fr/author/Tsuneo%20Kobayashi",
"affiliation": {
"@type": "Organization",
"name": "Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan. Electronic address: tkoba@hoshi.ac.jp."
}
},
{
"@type": "Person",
"name": "Rafal Jonczyk",
"url": "https://questionsmedicales.fr/author/Rafal%20Jonczyk",
"affiliation": {
"@type": "Organization",
"name": "Biotechnology of Natural Products, Technische Universität München, 85354 Freising, Germany."
}
},
{
"@type": "Person",
"name": "Thomas Hoffmann",
"url": "https://questionsmedicales.fr/author/Thomas%20Hoffmann",
"affiliation": {
"@type": "Organization",
"name": "Biotechnology of Natural Products, Technische Universität München, 85354 Freising, Germany."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "REM Behavior Disorder: Implications for PD Therapeutics.",
"datePublished": "2023-10-13",
"url": "https://questionsmedicales.fr/article/37831394",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11910-023-01310-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Neurofilament light chain and cardiac MIBG uptake as predictors for phenoconversion in isolated REM sleep behavior disorder.",
"datePublished": "2023-05-26",
"url": "https://questionsmedicales.fr/article/37233802",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00415-023-11785-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cerebellar Volume Reduction in Patients with Isolated REM Sleep Behavior Disorder: Evidence of a Potential Role of the Cerebellum.",
"datePublished": "2023-08-01",
"url": "https://questionsmedicales.fr/article/37527632",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1159/000533297"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cognitive and motor profiles as prodromal markers in predicting phenoconversion and phenotype in isolated REM sleep behavior disorder.",
"datePublished": "2023-10-28",
"url": "https://questionsmedicales.fr/article/37925853",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.sleep.2023.10.027"
}
},
{
"@type": "ScholarlyArticle",
"name": "Misfolded α-Synuclein Assessment in the Skin and CSF by RT-QuIC in Isolated REM Sleep Behavior Disorder.",
"datePublished": "2023-03-17",
"url": "https://questionsmedicales.fr/article/36931726",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1212/WNL.0000000000207147"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides nucléiques, nucléotides et nucléosides",
"item": "https://questionsmedicales.fr/mesh/D009706"
},
{
"@type": "ListItem",
"position": 3,
"name": "Nucléotides",
"item": "https://questionsmedicales.fr/mesh/D009711"
},
{
"@type": "ListItem",
"position": 4,
"name": "Ribonucléotides",
"item": "https://questionsmedicales.fr/mesh/D012265"
},
{
"@type": "ListItem",
"position": 5,
"name": "Nucléotides uridyliques",
"item": "https://questionsmedicales.fr/mesh/D014500"
},
{
"@type": "ListItem",
"position": 6,
"name": "Uridine diphosphate",
"item": "https://questionsmedicales.fr/mesh/D014530"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Uridine diphosphate - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Uridine diphosphate",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-12",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Uridine diphosphate",
"description": "Comment diagnostiquer une carence en UDP ?\nQuels tests sont utilisés pour évaluer l'UDP ?\nL'UDP peut-il être mesuré dans le sang ?\nQuels symptômes indiquent un problème d'UDP ?\nY a-t-il des marqueurs spécifiques pour l'UDP ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=REM+Sleep+Behavior+Disorder&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Uridine diphosphate",
"description": "Quels sont les symptômes d'une carence en UDP ?\nL'UDP affecte-t-il le système nerveux ?\nDes douleurs musculaires peuvent-elles être liées à l'UDP ?\nL'UDP influence-t-il l'humeur ?\nY a-t-il des signes cutanés associés à l'UDP ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=REM+Sleep+Behavior+Disorder&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Uridine diphosphate",
"description": "Comment prévenir une carence en UDP ?\nLes suppléments sont-ils nécessaires pour l'UDP ?\nY a-t-il des groupes à risque pour l'UDP ?\nLes habitudes de vie influencent-elles l'UDP ?\nDes conseils nutritionnels existent-ils pour l'UDP ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=REM+Sleep+Behavior+Disorder&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Uridine diphosphate",
"description": "Comment traiter une carence en UDP ?\nLes médicaments peuvent-ils aider à l'UDP ?\nY a-t-il des thérapies alternatives pour l'UDP ?\nLes changements alimentaires sont-ils efficaces ?\nDes traitements spécifiques existent-ils pour l'UDP ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=REM+Sleep+Behavior+Disorder&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Uridine diphosphate",
"description": "Quelles complications peuvent survenir avec une carence en UDP ?\nL'UDP peut-il affecter le développement ?\nDes maladies chroniques sont-elles liées à l'UDP ?\nL'UDP est-il impliqué dans des maladies héréditaires ?\nDes troubles immunitaires peuvent-ils être liés à l'UDP ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=REM+Sleep+Behavior+Disorder&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Uridine diphosphate",
"description": "Quels sont les facteurs de risque pour l'UDP ?\nL'âge influence-t-il les niveaux d'UDP ?\nLe stress peut-il affecter l'UDP ?\nLes maladies génétiques influencent-elles l'UDP ?\nLes habitudes alimentaires jouent-elles un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=REM+Sleep+Behavior+Disorder&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une carence en UDP ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests biochimiques mesurant les niveaux d'UDP dans les cellules peuvent être effectués."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'UDP ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests enzymatiques et chromatographiques sont couramment utilisés pour évaluer l'UDP."
}
},
{
"@type": "Question",
"name": "L'UDP peut-il être mesuré dans le sang ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'UDP est généralement mesuré dans les tissus plutôt que dans le sang en raison de sa faible concentration."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un problème d'UDP ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la fatigue, des troubles neurologiques ou des anomalies métaboliques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs spécifiques pour l'UDP ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de marqueurs spécifiques, mais des niveaux d'enzymes peuvent indiquer des anomalies."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une carence en UDP ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, faiblesse musculaire et troubles cognitifs."
}
},
{
"@type": "Question",
"name": "L'UDP affecte-t-il le système nerveux ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une carence en UDP peut entraîner des troubles neurologiques et cognitifs."
}
},
{
"@type": "Question",
"name": "Des douleurs musculaires peuvent-elles être liées à l'UDP ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs musculaires peuvent survenir en raison d'un métabolisme énergétique altéré."
}
},
{
"@type": "Question",
"name": "L'UDP influence-t-il l'humeur ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une carence en UDP peut affecter l'humeur et entraîner des troubles de l'humeur."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cutanés associés à l'UDP ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies cutanées peuvent apparaître, mais elles sont moins fréquentes."
}
},
{
"@type": "Question",
"name": "Comment prévenir une carence en UDP ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée riche en acides nucléiques peut aider à prévenir une carence."
}
},
{
"@type": "Question",
"name": "Les suppléments sont-ils nécessaires pour l'UDP ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les suppléments peuvent être bénéfiques, surtout en cas de régime alimentaire pauvre."
}
},
{
"@type": "Question",
"name": "Y a-t-il des groupes à risque pour l'UDP ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes ayant des troubles métaboliques ou des régimes restrictifs sont à risque."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie influencent-elles l'UDP ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes de vie saines, comme l'exercice, peuvent soutenir le métabolisme de l'UDP."
}
},
{
"@type": "Question",
"name": "Des conseils nutritionnels existent-ils pour l'UDP ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, consulter un nutritionniste peut aider à élaborer un plan alimentaire adapté."
}
},
{
"@type": "Question",
"name": "Comment traiter une carence en UDP ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement peut inclure des suppléments d'uridine et des modifications alimentaires."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider à l'UDP ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments peuvent améliorer le métabolisme de l'UDP, mais nécessitent une prescription."
}
},
{
"@type": "Question",
"name": "Y a-t-il des thérapies alternatives pour l'UDP ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies comme la nutrition ciblée peuvent être bénéfiques, mais nécessitent des études."
}
},
{
"@type": "Question",
"name": "Les changements alimentaires sont-ils efficaces ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en acides nucléiques peut aider à augmenter les niveaux d'UDP."
}
},
{
"@type": "Question",
"name": "Des traitements spécifiques existent-ils pour l'UDP ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de traitements spécifiques approuvés pour les troubles liés à l'UDP."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une carence en UDP ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications neurologiques et métaboliques peuvent survenir si non traitées."
}
},
{
"@type": "Question",
"name": "L'UDP peut-il affecter le développement ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une carence en UDP peut nuire au développement cognitif et physique chez les enfants."
}
},
{
"@type": "Question",
"name": "Des maladies chroniques sont-elles liées à l'UDP ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies métaboliques chroniques peuvent être exacerbées par une carence en UDP."
}
},
{
"@type": "Question",
"name": "L'UDP est-il impliqué dans des maladies héréditaires ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles héréditaires du métabolisme peuvent affecter les niveaux d'UDP."
}
},
{
"@type": "Question",
"name": "Des troubles immunitaires peuvent-ils être liés à l'UDP ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une carence en UDP peut affaiblir le système immunitaire, augmentant le risque d'infections."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour l'UDP ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les régimes alimentaires pauvres, les maladies métaboliques et le stress sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il les niveaux d'UDP ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les niveaux d'UDP peuvent diminuer avec l'âge, augmentant le risque de carence."
}
},
{
"@type": "Question",
"name": "Le stress peut-il affecter l'UDP ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut perturber le métabolisme de l'UDP et entraîner des carences."
}
},
{
"@type": "Question",
"name": "Les maladies génétiques influencent-elles l'UDP ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies génétiques peuvent affecter la synthèse et l'utilisation de l'UDP."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires jouent-elles un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation déséquilibrée peut augmenter le risque de carence en UDP."
}
}
]
}
]
}
Rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia that occurs during REM sleep, characterized by REM sleep without atonia (RSWA) and dream enactment behavior (DEB). RBD is associa...
Recent research recognizes RBD as a prodromal marker of PD, resulting in expansion of basic science and clinical investigations of RBD. Current basic science research investigates the pathophysiology ...
Isolated rapid-eye-movement (REM) sleep behavior disorder (iRBD) is considered as a prodromal stage of either multiple system atrophy (MSA) or Lewy body disease (LBD; Parkinson's disease and dementia ...
Forty patients with iRBD were enrolled between April 2018 and October 2019 and prospectively followed every 3 months to determine phenoconversion to either MSA or LBD. Plasma NfL levels were measured ...
Patients were followed for a median of 2.92 years. Four patients converted to MSA and 7 to LBD. Plasma NfL level at baseline was significantly higher in future MSA-converters (median 23.2 pg/mL) when ...
Plasma NfL and cardiac MIBG uptake may be useful biomarkers in predicting phenoconversion of iRBD. Elevated plasma NfL levels may suggest imminent phenoconversion to MSA, whereas low cardiac MIBG upta...
In this study, we aimed to investigate changes in the total cerebellar volume, subdivisions of the cerebellar volume, and intrinsic cerebellar network in patients with isolated rapid eye movement (REM...
We enrolled patients with newly diagnosed iRBD and healthy controls who had no structural lesions according to their brain MRI. All participants underwent three-dimensional T1-weighted imaging. We obt...
In total, we enrolled 43 patients with iRBD and 47 healthy controls. Total cerebellar volume in patients with iRBD was lower than that in the healthy controls (8.4637 vs. 9.0863%, p = 0.0001). There w...
We found decreased total cerebellar volumes and subdivisions of the cerebellar volume, particularly in the right and left lobule VIIB, in patients with iRBD compared to healthy controls. The present r...
To determine the clinical markers based on cognitive and motor profiles in predicting phenoconverion and phenotype in isolated rapid eye movement sleep behavior disorder (iRBD)....
45 iRBD patients and 25 healthy controls were included in the follow-up study. All participates received comprehensive evaluations of cognitive, motor and autonomic function at baseline. Positive phen...
21 iRBD patients displayed phenoconversion in a mean follow-up of 2.9 ± 1.6 years, with 14 presenting motor phenotype and 7 cognitive phenotype. In iRBD, visuospatial, memory, attention-executive func...
In iRBD, the attention-executive and motor function served as optimum combined markers in predicting phenoconversion and motor phenotype, whereas the attention-executive function performed best in pre...
Real-time quaking-induced conversion (RT-QuIC) assay detects misfolded α-synuclein (AS) in the skin and CSF of patients with the synucleinopathies Parkinson disease and dementia with Lewy bodies. Isol...
This was a cross-sectional study where consecutive patients with polysomnographic-confirmed IRBD and age-matched controls without RBD underwent skin biopsy and lumbar puncture the same day. Three-mill...
We recruited 91 patients with IRBD and 41 controls. In the skin, sensitivity to detect AS was 76.9% (95% CI 66.9-85.1), specificity 97.6% (95% CI 87.1-99.9) positive predictive value 98.6% (95% CI 91....
Our study in IRBD shows that (1) RT-QuIC detects AS in the skin and CSF with similar high sensitivity, specificity, and agreement, (2) AS RT-QuIC positivity is associated with supportive features and ...
This study provides Class III evidence that RT-QuIC-detected AS in the skin and CSF distinguishes patients with IRBD from controls....
This study aimed to correlate REM sleep without atonia (RSWA) and neuropsychological data in patients with idiopathic/isolated REM sleep behaviour disorder (iRBD) and those with RBD associated with Pa...
Previous studies have shown that rapid eye movement sleep without atonia during polysomnography can predict the risk of phenoconversion to neurodegenerative disease in patients with isolated rapid eye...
To evaluate the prevalence of REM sleep behavior disorder (RBD) and its possible prodromal conditions, isolated dream enactment behavior (DEB) and isolated REM without atonia (RWA), in a general popul...
From a population-based prospective cohort in Korea, 1,075 participants (age 60.1 ± 7.0 years; range 50-80 years; men 53.7%) completed the RBD screening questionnaire (RBDSQ), a structured telephone i...
RBD was diagnosed in 20 participants, isolated RWA in 133 participants, and isolated DEB in 48 participants. Sex and DEB frequency-adjusted prevalence of RBD was 1.4% (95% CI 1.0%-1.8%), isolated RWA ...
This study provides prevalence estimates of RBD and its possible prodromal conditions based on a structured telephone interview and RWA measurement on PSG from the general population....
Rapid-eye movement (REM) sleep behavior disorder (RBD), enactment of dreams during REM sleep, is an early clinical symptom of alpha-synucleinopathies and defines a more severe subtype. The genetic bac...
The microbiota-gut-brain axis has been suggested to play an important role in Parkinson's disease (PD). Here we performed a cross-sectional study to profile gut microbiota across early PD, REM sleep b...